Results 161 to 170 of about 23,127 (334)

Intestinal epithelial injury and inflammation after physical work in temperate and hot environments in older men with hypertension or type 2 diabetes

Experimental Physiology, EarlyView.
Abstract We tested whether older adults with well‐controlled type 2 diabetes or hypertension, compared with age‐matched adults without chronic disease, exhibit greater intestinal damage, microbial translocation and inflammation during exertional heat stress.
Ben J. Lee, Tessa R. Flood, Sophie L. Russell, James J. McCormick, Kelli E. King, Naoto Fujii, Tatsuro Amano, Sean Notley, Glen P. Kenny   +8 more
wiley   +1 more source

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus

Терапевтический архив, 2014
AIM. To study the secretion of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 2 (GLP-2) in response to a carbohydrate load in people with risk factors for type 2 diabetes mellitus (DM2) in ...
E A Shestakova, A V Il'in, M V Shestakova, I I Dedov   +3 more
doaj  

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers [PDF]

, 2011
Miyako Kishimoto, Mitsuhiko Noda
core   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

The Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild, Valdemar Brimnes Ingemann Johansen, Christoffer Clemmensen, Pablo Ranea‐Robles   +3 more
wiley   +1 more source

Pancreatic Islet Cell Crosstalk: Insight Into α‐/β‐Cell Compensatory Mechanisms

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
α‐cell remodeling compensates for impaired β‐cell function. Intra‐islet glucagon/GLP‐1 signaling is upregulated and becomes essential in prediabetic islets. Flexible receptor engagement reflects functional plasticity in hormonal control of insulin secretion. Created in BioRender. Plecita, L. (2026); https://BioRender.com/pgjjg3m.
Štěpánka Benáková, Blanka Holendová, Jurij Dolenšek, Monika Křivonosková, Andraž Stožer, Lydie Plecitá‐Hlavatá   +5 more
wiley   +1 more source

Unimolecular GLP‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4706-4717, June 2026.
ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar, Ethan S. Palmer, Sarah L. Craig, Elzbieta Krason‐Kidzinska, Nigel Irwin, Finbarr P. M. O'Harte   +5 more
wiley   +1 more source

Obituary for Prof. Dr. med. Dr. h. c. Werner Creutzfeldt, FRCP [PDF]

, 2006
Göke, Burkhard
core   +1 more source

Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4847-4859, June 2026.
ABSTRACT Background Type 2 diabetes mellitus (T2DM) is a progressive, multi‐organ disorder that often requires intensive combination therapy. This Phase III, randomised, double‐blind, placebo‐controlled study evaluated the efficacy and safety of two fixed‐dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or ...
Soo Lim, Tae Nyun Kim, Ji Oh Mok, Choon Hee Chung, You Cheol Hwang, Ho Chan Cho, Jong Chul Won, Eonju Jeon, Eun Seok Kang, Ki Young Lee, Chong Hwa Kim, Soo Heon Kwak, Cheol Young Park, Kang Seo Park, Sang Yong Kim, Jae Hyuk Lee, Soon Hee Lee, Dong Hyeok Cho, Hyuk‐Sang Kwon, Kyung Ah Han   +19 more
wiley   +1 more source

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source